How the investment model prices a ramp timeline
When a multi-site platform underwrites a new location, the investment model includes a ramp timeline – the projected months from opening to maturity-level EBITDA contribution. That timeline is not a soft assumption. It is a hard input in the IRR calculation. The model priced in a ramp timeline, and every month the actual ramp runs slower than modeled is a direct, calculable hit to portfolio IRR. Not because revenue is declining. Because it is not growing fast enough to satisfy the underwriting assumption.
Most underwriting models acknowledge this risk in the abstract. Fewer build the pre-opening marketing investment required to mitigate it into the launch budget. That gap between modeling the ramp risk and funding the solution is where most De Novo underperformance originates.
Running the numbers: what six months of ramp delay actually costs
The calculation is straightforward. Consider a new location modeled to reach full EBITDA contribution of $200,000 annually by month 12, but that actually reaches it by month 18. The six-month gap represents $100,000 in below-model EBITDA contribution on that single location – capital that was priced into the IRR at full return but delivered at partial return for half a year.
Scale that across a platform opening 10 new locations per year, all running six months behind their ramp models: $1 million in annual EBITDA shortfall, recurring every year as new locations open and underperform. At a 10x EBITDA multiple – conservative for PE-backed healthcare – that recurring shortfall represents $10 million in suppressed enterprise value.
Why the investigation usually looks in the wrong place
When a new location underperforms its ramp model, the investigation almost always starts with operations: staffing levels, scheduling efficiency, front-desk conversion rates, clinical capacity utilization. These are legitimate variables and worth examining. But more often than not, the root cause is not operational. It is a patient acquisition pipeline that was never built before opening day.
Operations cannot schedule patients who don’t know the practice exists. A location with excellent clinical capacity and a fully staffed team is still going to underperform its ramp model if awareness is low and the appointment book is thin. Marketing creates the demand that operations converts and retains. When marketing starts late, operations is working with the inventory it has – which in the early months is not enough.
The misdiagnosis compounds the problem. Remediation effort goes to the wrong lever, which delays the fix. And because underperformance gets attributed to market conditions or staffing rather than a correctable gap in launch sequencing, the same mistake gets made at the next opening.
The cost of starting four weeks out instead of ninety days
The most common De Novo marketing failure is starting four to six weeks before opening rather than 90 days before. The difference is not just timing – it is the compounding cost of everything that doesn’t happen in the window that was missed. A Google Business Profile established 90 days before opening has time to accumulate views, build local search authority, and rank organically before the first appointment is scheduled. One established two weeks before opening starts with none of that.
A pre-registration campaign running for 90 days before opening can fill the first two to three weeks of the schedule with committed patients. One running for four weeks fills a few slots. The cost of the 60-day shortfall is not just the awareness that wasn’t built – it is the compounding ramp advantage that was forfeited, month after month, through the entire six-to-nine-month critical window.
Systems hit ramp models. Campaigns don’t.
Multi-site platforms that consistently hit their De Novo ramp models share one structural characteristic: they treat new location marketing as a defined, repeatable process – not a campaign activated when construction is complete. The launch playbook exists before the location is selected. The pre-opening timeline is built into the opening budget. The pre-registration infrastructure is ready to deploy 90 days out, regardless of market, specialty, or competitive environment.
The platforms that miss their ramp models consistently tend to do so for consistent reasons: marketing starts late, pre-opening investment is treated as discretionary, and the launch is treated as an event rather than a process.
The difference between hitting and missing the model is rarely market conditions or clinical team quality. It is whether a system was in place or a campaign was improvised. Systems are replicable. Improvised campaigns are not – and their results aren’t either.
Building the business case: what the ROI calculation actually shows
The business case comes down to one comparison: what a ramp delay costs versus what it costs to prevent it. At a location with $200,000 in annual mature EBITDA, the monthly shortfall during a ramp delay runs approximately $8,000 to $12,000 depending on how far below model the location is performing. A six-month delay generates $48,000 to $72,000 in EBITDA that was in the model and not delivered.
A pre-opening marketing program at that location typically costs $30,000 to $60,000, fully loaded through the first six months of operation. That math does not require a financial model to close.
“Most underwriting models price in the ramp risk. Almost none fund the one investment that reduces it.”
Agency Creative helps multi-site CMOs build the business case for De Novo marketing investment using actual location data – and then delivers the launch infrastructure that justifies it. Let’s run the numbers for your next opening.
Learn how Agency Creative can help boost your brand by calling us at 972.488.1660 or by contacting us online.
See More Work
